BAKER BROS. ADVISORS LP - 15 May 2025 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Reporting relationship: Director
Issuer ticker: IMCR
Reported as of: 15 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2025, 16:04:28 UTC
Prior SEC filing: 02 Apr 2025
Next SEC filing: 22 May 2025
Source filing: View source filing
Reporting owner signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing

Key filing fact

BAKER BROS. ADVISORS LP filed Form 4 for Immunocore Holdings plc (IMCR) on 19 May 2025.

Key facts

This page summarizes BAKER BROS. ADVISORS LP's Form 4 filing for Immunocore Holdings plc (IMCR).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 May 2025, 16:04.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (6)

CIK 0001263508 Primary reporting owner

BAKER BROS. ADVISORS LP

Relationship: Director
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 19 May 2025

CIK 0001551139

667, L.P.

Relationship: Director
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 19 May 2025

CIK 0001580575

Baker Bros. Advisors (GP) LLC

Relationship: Director
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing
Signature date: 19 May 2025

CIK 0001363364

Baker Brothers Life Sciences LP

Relationship: Director
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P., Name: /s/ Scott L. Lessing, Title: President
Signature date: 19 May 2025

CIK 0001087940

BAKER FELIX

Relationship: Director
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Felix J. Baker
Signature date: 19 May 2025

CIK 0001087939

BAKER JULIAN

Relationship: Director
Address: 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK
Signature: /s/ Julian C. Baker
Signature date: 19 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMCR transaction Derivative

Non-Qualified Share Option (right to buy)

Award

Transaction value: $0
Shares: +26,198
Change %
Price: $0.000000
Shares after: 26,198
Date: 15 May 2025
Ownership: See Footnotes
Underlying class: Ordinary Shares
Underlying amount: 26,198
Exercise price: $29.06
Footnotes: F1, F2, F3, F4, F5, F6, F7, F8

IMCR transaction Derivative

Non-Qualified Share Option (right to buy)

Award

Transaction value: $0
Shares: +26,198
Change %
Price: $0.000000
Shares after: 26,198
Date: 15 May 2025
Ownership: See Footnotes
Underlying class: Ordinary Shares
Underlying amount: 26,198
Exercise price: $29.06
Footnotes: F1, F2, F3, F4, F6, F7, F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Includes 26,198 non-qualified share options ("Share Options") exercisable solely into ordinary shares ("Ordinary shares") of Immunocore Holdings plc (the "Issuer") granted by the Issuer to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on May 15, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2021 Equity Incentive Plan (the "Incentive Plan"). The Share Options have a strike price of $29.06 per share, and vest on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of shareholders of the Issuer, subject to Ranjeev Krishana's continued service on the board of directors of the Issuer (the "Board") through the vesting date. The Share Options expire on May 14, 2035.

Footnote F2

Ranjeev Krishana serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

Footnote F3

The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

Footnote F4

Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Footnote F5

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Share Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

Footnote F6

The acquisition of Share Options reported on this form represents a single grant to Ranjeev Krishana of 26,198 Share Options on Table II. This grant of 26,198 Share Options for Ranjeev Krishana is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

Footnote F7

Pursuant to the policies of the Adviser, Ranjeev Krishana does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary shares, Share Options and Ordinary shares issued upon exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

Footnote F8

Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options and any Ordinary shares received as a result of the exercise of Share Options.

Footnote F9

After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Share Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC remarks

Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP, is a director of Immunocore Holdings plc (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.